✦ LIBER ✦

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

✍ Scribed by Steensma, David P. (author);Dewald, Gordon W. (author);Lasho, Terra L. (author);Powell, Heather L. (author);McClure, Rebecca F. (author);Levine, Ross L. (author);Gilliland, D. Gary (author);Tefferi, Ayalew (author)

Book ID: 121814266
Publisher: American Society of Hematology
Year: 2005
Tongue: English
Weight: 116 KB
Volume: 106
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2005-03-1183

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The JAK2 V617F activating tyrosine kinas

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

✍ Steensma, David P. (author);Dewald, Gordon W. (author);Lasho, Terra L. (author); 📂 Article 📅 2005 🏛 American Society of Hematology 🌐 English ⚖ 116 KB

The JAK2 V617F tyrosine kinase mutation

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

✍ Ohyashiki, K; Aota, Y; Akahane, D; Gotoh, A; Miyazawa, K; Kimura, Y; Ohyashiki, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB

The JAK2V617F Tyrosine Kinase Mutation i

The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis

✍ Tefferi, Ayalew; Gilliland, D. Gary 📂 Article 📅 2005 🏛 Mayo Clinic 🌐 English ⚖ 158 KB